ELTX

Elicio Therapeutics, Inc.

ELTX · CIK 1601485 · Annual (10-K) · Last 4 years

Financial Trends

Revenue
20212024
Net Income−$52M
20212024
Operating CF−$37M
20212024
Free Cash Flow−$37M
20212024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue——$0.0B$0.0B
Cost of Revenue——$0.0B$0.0B
Gross Profit————
R&D Expense$0.0B$0.0B$0.0B$0.0B
SG&A Expense————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.1B$-0.0B$-0.0B$-0.1B
EPS (Basic)$-4.25$-6.96$-1.29$-1.93
EPS (Diluted)$-4.25$-6.96$-1.29$-1.93

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.0B$0.0B$0.1B$0.1B
Current Assets$0.0B$0.0B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.1B$0.1B
Total Liabilities$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$-0.0B$0.0B$0.0B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.1B
Investing Cash Flow$-0.0B$-0.0B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$-0.0B$0.1B
← Companies